Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov 1;235(5):788-798.
doi: 10.1097/XCS.0000000000000326. Epub 2022 Oct 17.

Impact of Surgical Delay on Tumor Upstaging and Outcomes in Estrogen Receptor-Negative Ductal Carcinoma in Situ Patients

Amanda E Deliere  1 , Kristine M Kuchta  2 , Catherine E Pesce  1 , Katherine A Kopkash  1 , Katharine A Yao  1
Affiliations

Impact of Surgical Delay on Tumor Upstaging and Outcomes in Estrogen Receptor-Negative Ductal Carcinoma in Situ Patients

Amanda E Deliere et al. J Am Coll Surg. .

Abstract

Background: The delay of elective surgeries by the coronavirus 2019 (COVID-19) pandemic prompted concern among surgeons to delay estrogen receptor (ER)-negative ductal carcinoma in situ (DCIS) for fear of missing an ER-negative invasive cancer and compromising survival of patients.

Study design: Female patients ≥40 years old diagnosed with ER-negative DCIS from 2004 to 2017 were examined from the National Cancer Database. Multivariable logistic regression, adjusting for patient and tumor factors, was used to determine factors associated with tumor upstage. Multivariable Cox proportional hazards modeling was used to determine if surgical delay impacted overall survival of ER-negative DCIS patients that were upstaged to invasive disease.

Results: There were 219,731 patients with DCIS of which 24,338 (11.1%) had tumor upstage. Of these patients, 5,675 (16.2%) of ER-negative and 18,663 (10.1%) of ER-positive DCIS patients were upstaged (p ≤ 0.001). From 2004 to 2017, ER-negative DCIS upstage rates increased from 12.9% to 18.9%. Independent factors associated with tumor upstage were younger age (odds ratio [OR] 0.75 [95% CI 0.69 to 0.81]) and Black race (OR 1.34 [95% CI 1.22 to 1.46]). Compared with patients with ≤30 days between biopsy and surgery, patients with a 31- to 60-day interval (OR 1.13 [95% CI 1.05 to 1.20]) and a >60-day interval (OR 1.12 [95% CI 1.02 to 1.23]) had an increased rate of tumor upstage. Among ER-negative DCIS patients whose tumors were upstaged to invasive disease, Cox proportional hazard regression modeling showed no association between the number of days between biopsy and surgery and overall survival.

Conclusions: Delays in surgery were associated with higher tumor upstage rates but not with worse overall survival.

PubMed Disclaimer

References

    1. COVID-19 guidelines for triage of breast cancer patients. Chicago, IL: American College of Surgeons; March 24, 2020. Available at: https://www.facs.org/covid-19/clinical-guidance/elective-case/breast-cancer . Accessed January 9, 2022.
    1. The American Society of Breast Surgeons. Recommendations for prioritization, treatment, and triage of breast cancer patients during the COVID-19 pandemic: executive summary. March 24, 2020. Available at: https://www.breastsurgeons.org/docs/news/The_COVID-19_Pandemic_Breast_Ca... . Accessed on January 9, 2022.
    1. The COVID-19 Pandemic Breast Cancer Consortium. Recommendations for prioritization, treatment, and triage of breast cancer patients during the COVID-19 pandemic. Available at: https://www.facs.org/-/media/files/quality-programs/napbc/asbrs_napbc_co... . Accessed on January 9, 2022.
    1. Bartlett DL, Howe JR, Chang G, et al.; Society of Surgical Oncology. Management of cancer surgery cases during the COVID-19 pandemic: considerations. Ann Surg Oncol. 2020;27:1717–1720.
    1. Chavez de Paz Villanueva C, Bonev V, Senthil M, et al. Factors associated with underestimation of invasive cancer in patients with ductal carcinoma in situ: precautions for active surveillance. JAMA Surg. 2017;152:1007–1014.

Substances